Home   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
VEGFR

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

VEGFR

Chemical Structure Cat. No. Product Name CAS No.
Ningetinib Chemical Structure
BCP46143 Ningetinib 1394820-69-9
Ningetinib is a novel tyrosine kinase inhibitor, targeted at c-Met, Axl, VEGFR-2, Mer and Flt3.
Tivozanib hydrochloride hydrate Chemical Structure
BCP45190 Tivozanib hydrochloride hydrate 682745-41-1
Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities.
XL-092 Chemical Structure
BCP40284 XL-092 2367004-54-2
XL092 is an investigational, next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in the growth and spread of cancer.
HS-1793 Chemical Structure
BCP37847 HS-1793 927885-00-5
HS-1793, inhibits hypoxia-induced HIF-1α and VEGF expression, and migration in human prostate cancer cells.
Acrizanib Chemical Structure
BCP36110 Acrizanib 1229453-99-9
Acrizanib is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-KDR.
SAR131675 Chemical Structure
BCP35024 SAR131675 1433953-83-3
SAR131675 is a potent and selective VEGFR3 inhibitor with an IC50 of 23 nM.
(Z)-Guggulsterone Chemical Structure
BCP07472 (Z)-Guggulsterone 39025-23-5
Z-guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. Z-guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis.
5Z-7-Oxozeaenol Chemical Structure
BCP34467 5Z-7-Oxozeaenol 253863-19-3
5Z-7-Oxozeaenol is a covalent inhibitor that acts against the several protein kinases (e.g. ERK2 and TAK1) that possess a free cysteine at the gatekeeper-2 position.
Donafenib Chemical Structure
BCP34023 Donafenib 1130115-44-4
Donafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).
TAS-115 mesylate Chemical Structure
BCP34015 TAS-115 mesylate 1688673-09-7
TAS-115 mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
123下一页末页共 133 条记录 1 / 14 页 
0086-13720134139